Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2006 by Martini Hospital Groningen.
Recruitment status was  Recruiting
Information provided by:
Martini Hospital Groningen Identifier:
First received: February 7, 2006
Last updated: February 17, 2006
Last verified: February 2006

We want to study the effect of the combination of metoprolol (a beta-blocker) with formoterol (a beta-agonist) on long function in patients with Chronic Obstructive Pulmonary Disease (COPD). There are more and more clues that a beta-blocker, when well chosen and in the right dosage, won't harm the long function in patients with COPD. Since a beta-blocker can be a valuable addition to treating patients with heart problems we would like to see if this category of medication can be available for COPD patients in the future.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Metoprolol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD

Resource links provided by NLM:

Further study details as provided by Martini Hospital Groningen:

Primary Outcome Measures:
  • Difference in airway reactivity after treatment with metoprolol compared to placebo.

Secondary Outcome Measures:
  • Effect of formoterol on airway reactivity comparing metoprolol with placebo.
  • Borg-scores during provocation test
  • Peak-flow measurements
  • CCQ-scores
  • Exacerbation rate and rescue medication use

Estimated Enrollment: 45
Study Start Date: February 2006

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • male/female aged between 40-70 inclusive
  • COPD defined by GOLD criteria
  • FEV1 greater or equal to 60% of predicted without medication
  • baseline FEV1 greater or equal than 1.2L
  • 10 or more pack years
  • no hard contraindications for use of beta blockers
  • being able to perform technically acceptable pulmonary function tests
  • signed informed consent
  • systolic blood pressure equal to 130 or greater

Exclusion Criteria:

  • instable COPD during the month before visit 1
  • usage of corticosteroids during the month before visit 1
  • significant pulmonary diseases other than COPD
  • a history of cancer within the last 5 years (basal cell carcinoma or cutaneous squamous cell carcinoma allowed)
  • a recent history of myocardial infarction
  • use of an investigational drug within one month or six half lives (which ever is greater) of visit 1
  • contra-indications for the use of ipratropium-bromide
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00288548

Contact: Mirjam Mensing, Drs. +31 50 524 7817

Martini Hospital Recruiting
Groningen, Netherlands, 9700 RM
Sponsors and Collaborators
Martini Hospital Groningen
Principal Investigator: René Aalbers, MD, PhD Martini Hospital Groningen
  More Information

No publications provided Identifier: NCT00288548     History of Changes
Other Study ID Numbers: MeFCo2
Study First Received: February 7, 2006
Last Updated: February 17, 2006
Health Authority: Netherlands: Independent Ethics Committee

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Metoprolol succinate
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 25, 2014